Gilteritinib

Abstract

Introduction

Acute myeloid leukemia (AML) is a heterogeneous and aggressive form of blood cancer that affects the myeloid lineage of the cells. Among various genetic mutations associated with AML, the FLT-3 mutation is one of the most common and associated with poor prognosis. Gilteritinib (previously known as ASP2215) is the first tyrosine kinase inhibitor approved as monotherapy for treatment of relapsed/refractory AML.

Areas Covered

We review gilteritinib in detail, including its mechanism of action, pharmacology, efficacy, toxicity profile, and key clinical trials.

Keywords

FLT3 mutation - relapsed/refractory AML - TKI - gilteritinib

Patient Consent

Patient consent is not required.

Publikationsverlauf

Artikel online veröffentlicht:
10. Juli 2025

• References

• 1 Perl AE, Martinelli G, Cortes JE. et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 2019; 381 (18) 1728-1740
• 2 Levis M, Perl AE. Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Adv 2020; 4 (06) 1178-1191
• 3 Pratz KW, Cherry M, Altman JK. et al. Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy: a phase IB study in patients with newly diagnosed AML. J Clin Oncol 2023; 41 (26) 4236-4246
• 4 Astellas Pharma US, Inc. Highlights of prescribing information [Internet]. Northbrook, IL: Astellas Pharma US, Inc.; 2018 . Accessed April 4, 2025 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf
• 5 McMahon CM, Canaani J, Rea B. et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv 2019; 3 (10) 1581-1585
• 6 Levis MJ, Hamadani M, Logan B. et al; BMT-CTN 1506/MORPHO Study Investigators. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3 . J Clin Oncol 2024; 42 (15) 1766-1775
• 7 Daver N, Perl AE, Maly J. et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia. J Clin Oncol 2022; 40 (35) 4048-4059
• 8 Janssen M, Schmidt C, Bruch PM. et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. Blood 2022; 140 (24) 2594-2610
• 9 Wang ES, Montesinos P, Minden MD. et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood 2022; 140 (17) 1845-1857
• 10 Maiti A, DiNardo CD, Daver NG. et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 2021; 11 (02) 25
• 11 Abuasab T, Kantarjian H, Garcia-Manero G. et al. Phase II study of cladribine, idarubicin, cytarabine (CLIA) plus gilteritinib in patients with FLT3 mutated acute myeloid leukemia (AML). Blood 2021; 138 (Supplement 1): 2330
• 12 Numan Y, Abdel Rahman Z, Grenet J. et al. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol 2022; 97 (03) 322-328
• 13 Gyan E, Minden MD, Kubo K. et al. Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: a phase 2 study. Cancer 2025; 131 (04) e35746
• 14 Shatilova A, Budaeva I, Matvienko Y. et al. Myeloid sarcoma or extramedullary acute myeloid leukemia: experience in managing single-centre patients cohort. Blood 2024; 144 (Supplement 1): 5987
• 15 HOVON Foundation. . Gilteritinib versus midostaurin in FLT3 mutated acute myeloid leukemia. ClinicalTrials.gov Identifier: NCT04027309. Amsterdam: HOVON; 2018 [updated June 13, 2023]. Accessed April 08, 2025 at: https://clinicaltrials.gov/study/NCT04027309
• 16 Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv 2022; 6 (07) 2144-2155